Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Inducción Hospitalización AGOSTO 2021
Inducción Hospitalización AGOSTO 2021
Inducción Hospitalización AGOSTO 2021
PRÁCTICA HOSPITALARIA
Teaching
Slide Set
(SAMA) ● 0.5 mg (2 ml) cada 30 min por 1 hora, luego 2-4 horas según sea necesario
Bromuro de ● 4-8 puff según sea necesario
ipratropio
(ICS)
● 200-400 ug cada 8 horas, luego cada 12 horas
Budesonida
ó ● 250 ug cada 8 horas
Fluticasona
NO EJERCICIOS DE
REEXPANSION DE PACIENTE
EN CRISIS DE
BRONCOESPASMO
Global Initiative for Asthma (GINA)
What’s new in GINA 2022?
CONTROL DE SINTOMAS.
• Reducir la carga para el paciente
• Evitar establecer un patrón de confianza del paciente en SABA
temprano en el curso de la enfermedad.
Confirmation of diagnosis if necessary
Adults & adolescents Symptom control & modifiable
12+ years risk factors (see Box 2-2B)
Comorbidities
Personalized asthma management Inhaler technique & adherence
Patient preferences and goals
Assess, Adjust, Review
for individual patient needs
Symptoms
Exacerbations
Side-effects
Lung function Treatment of modifiable risk factors
and comorbidities
Patient satisfaction
Non-pharmacological strategies
Asthma medications (adjust down/up/between tracks)
Education & skills training
STEP 5
Add-on LAMA
STEP 4
Refer for assessment
STEP 3 Medium dose of phenotype. Consider
CONTROLLER and maintenance
STEPS 1 – 2 Low dose
ICS-formoterol
high dose maintenance
PREFERRED RELIEVER As-needed low dose ICS-formoterol maintenance ICS-formoterol,
(Track 1). Using ICS-formoterol ICS-formoterol ± anti-IgE, anti-IL5/5R,
as reliever reduces the risk of anti-IL4R, anti-TSLP
exacerbations compared with See GINA
RELIEVER: As-needed low-dose ICS-formoterol severe
using a SABA reliever
asthma guide
STEP 5
STEP 4 Add-on LAMA
Refer for assessment
STEP 3 Medium/high
dose maintenance of phenotype. Consider
CONTROLLER and STEP 2 Low dose high dose maintenance
ICS-LABA
ALTERNATIVE RELIEVER STEP 1 Low dose maintenance ICS-LABA, ± anti-IgE,
(Track 2). Before considering a Take ICS whenever maintenance ICS ICS-LABA anti-IL5/5R, anti-IL4R,
regimen with SABA reliever, SABA taken anti-TSLP
check if the patient is likely to be
adherent with daily controller
RELIEVER: As-needed short-acting beta2-agonist
Symptoms
Exacerbations
Side-effects
Lung function Treatment of modifiable risk factors
Child and parent & comorbidities
satisfaction Non-pharmacological strategies STEP 5
Asthma medications (adjust down or up)
Education & skills training Refer for
phenotypic
Asthma medication options:
STEP 4 assessment
Adjust treatment up and down for ± higher dose
individual child’s needs Medium dose
STEP 3 ICS-LABA or
ICS-LABA, add-on therapy,
STEP 2 Low dose ICS- OR low dose† e.g. anti-IgE,
PREFERRED STEP 1 LABA, OR medium ICS-formoterol
Daily low dose inhaled corticosteroid (ICS) anti-IL4R
CONTROLLER dose ICS, OR maintenance
Low dose ICS (see table of ICS dose ranges for children)
to prevent exacerbations very low dose* and reliever
and control symptoms taken whenever
ICS-formoterol therapy (MART).
SABA taken
maintenance and Refer for expert
reliever (MART) advice
Consider daily Daily leukotriene receptor antagonist (LTRA), or Low dose Add tiotropium Add-on anti-IL5
Other controller options
low dose ICS low dose ICS taken whenever SABA taken ICS + LTRA or add LTRA or, as last resort,
(limited indications, or
consider add-on
less evidence for efficacy
low dose OCS, but
or safety)
consider side-effects
RELIEVER As-needed short-acting beta2-agonist (or ICS-formoterol reliever in MART in Steps 3 and 4)
AGUDA
- Instilación + DRR
- DRR sin instilación -
Lavado nasal
- ELPR
LAVADO O DUCHA NASAL
DRR
DRR
ELPr – AFE lenta y rápida en niños
Qx TORAX-ABDOMEN
TORACOTOMIA
TORACOSTOMIA
INTERVENCION EN Qx TORAX
• Control del dolor
• Liberar-desbloquear el diafragma
• Ejercicios de reexpansión
• Lograr AMA completo de hombro
• Deambulación precoz
• Alineación Postural